Navigation Links
Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
Date:9/15/2010

Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and... -- MINNEAPOLIS, Minnesota, September 15, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries, FDA Approval Click to view news release full screen  

Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture

 

MINNEAPOLIS, Minnesota, September 15, 2010 /PRNewswire/ -- Angioslide, Inc. of Minneapolis, MN and Angioslide, Ltd. Herzliya, Israel, announced today that the company has commercialized the Proteus device for Embolic Capture Angioplasty (ECA) in the United States. The device combines an angioplasty balloon and embolic capture feature into one device, thus providing physicians with a simple and cost-effective method of capturing of embolic particles during angioplasty procedures. Proteus is a one of its kind device to combine balloon angioplasty and embolic capture to receive FDA clearance, which was received in April 2010. The Proteus device is presently indicated for use in the lower limbs during Percutaneous Transluminal Angioplasty (PTA) procedures.

Proteus joins the new class of medical devices aimed at treating peripheral arterial disease (PAD), one of the fastest-growing segments in the worldwide interventional marketplace. An estimated 10 million patients suffer from PAD in the U.S. alone, of whom approximately 1,000,000 undergo a revascularization or amputation procedure each year. PTA procedures are a common treatment for peripheral artery disease for opening up the artery to improve blood flow. However, one potential complication of a PTA procedure is debris from the artery wall being disturbed during the procedure and floating through the blood stream. In the worst case this floating debris can totally occlude the artery and cause complete lack of circulation to the lower limb.

The Proteus device combines a standard angioplasty balloon with a feature that can capture the debris that maybe liberated during the PTA procedure. Proteus has the same characteristics as a standard angioplasty balloon but the embolic capture feature allows debris to be trapped within the balloon and removed as the physician removes the angioplasty balloon at the end of the PTA procedure.

"We believe that Proteus and Embolic Capture Angioplasty (ECA) represents a major advancement in the approach to angioplasty procedures. We are actively commercializing the Proteus in the U.S. via our direct sales force. In a relatively short time we are already active in over 15 hospitals in US and are very pleased with the acceptance of the device," said Doron Besser, President and CEO of Angioslide

Besser added, "This entry of Proteus into the U.S. market for is expected to be only the first in a series of applications of the technology such as the coronary, renal and carotid vascular beds.

"I am very pleased with the use of the Proteus device in my patients. It is simple to use and cost effective and I can now be assured that my patients will have a significant reduction in risk from the PTA procedure," said Dr. Subhash Banerjee, Chief, Division of Cardiology, from VA North Texas Health Care System, Dallas, TX.

"Being part of the company's Scientific Advisory Board from its early days, I am very excited that Proteus has received FDA clearance for use in the lower limbs. Proteus and Embolic Capture Angioplasty will reduce the risk of complications for our patients and in the future could become the gold standard for angioplasty procedures," said Dr. John Laird, Medical Director, UC Davis Vascular Center, Sacramento, CA.

Investors in Angioslide include Ofer Hi-Tech, Viola Group, Itochu Corporation and Agate Medical Investments.

United States operations are led by Tom Doorley, Senior VP of Sales, and John Schorgl, both former executives with Schneider/Pfizer.

About Angioslide

Angioslide is a privately held company with headquarters in Herzliya, Israel. Its U.S. distribution headquarters is located in Minneapolis, MN. Its European distribution headquarters is located in Karlsruhe, Germany.

The Proteus product line, Embolic Capture Angioplasty and ECA are trademarks of Angioslide Ltd.

Note: This press release contains forward-looking statements that are based upon management's present expectations and are essentially uncertain. Actual results and timing of events could differ materially from current expectations and from any forward-looking statements.

The company's first product is Proteus which is indicated for use in the United States for usage in the lower limbs. Angioslide can be contacted at +972-9-970-3700 or info@angioslide.com


'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Los innovadores ... del mundo, introduce catéteres para la intervención de ... una compañía global especializada en el suministro de ... su cartera incluyendo productos para tratar la enfermedad ... PTA son los dispositivos de primera entrada de ...
(Date:5/24/2016)... -- Een app die artsen over de ... kunnen behandelen, hun kennis kunnen delen en van elkaar ... en revolutionaire MDLinking App, ontwikkeld door een internationale groep ... Flu en oncologisch chirurg dr. Gijs van Acker ... op dinsdag 24 mei officieel gepresenteerd op het Amsterdam ...
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
Breaking Medicine Technology:
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene ... billion women around the world who do not have access to a toilet, even when ... about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on the ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria Health Announces ... Begin In June , Aloria Health, specializing in a re-imagined, client-oriented approach to ... Milwaukee, its first treatment facility for outpatient, day treatment and residential care. Aloria ...
(Date:5/24/2016)... ... May 24, 2016 , ... Global ... and education, today announced that it has named Scott Santarella as its new ... Addario Lung Cancer Foundation (ALCF) in San Francisco, where he successfully helped to ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Dignity Health has ... month. The new facility is licensed under Dignity Health Arizona General Hospital, which ... of Dignity Health in Arizona, said that the new facility will complement Dignity Health’s ...
Breaking Medicine News(10 mins):